Skip to main content
Premium Trial:

Request an Annual Quote

Sophia Genetics Obtains CE-IVD Mark for Bioinformatics Pipeline

NEW YORK (GenomeWeb) – Sophia Genetics said today that it has obtained the CE-IVD Mark for its next-generation sequencing bioinformatics pipeline for routine genetic testing.

The CE-IVD Mark enables the Lausanne, Switzerland-based firm to offer the pipeline in all markets accepting the CE mark in Europe, Latin America, Middle East, Africa, and Asia. Sophia said that it will also seek to obtain the CE Mark for all of the genetic tests it supports.

"The barrier to wider adoption of next-generation sequencing data for the routine genetic testing of patients has historically been the challenge associated with analyzing data," Jurgi Camblong, CEO of Sophia Genetics, said in a statement. "We have designed solutions to address even the most difficult data analysis problems that existing bioinformatics software programs are not able to solve, making NGS genetic testing much simpler, faster, and easier for our lab customers."

Sophia also noted that it recently received ISO 13485 accreditation, which covers requirements for quality management systems. The firm said that clinical labs using its service " gain access to quality assurance expertise, facilitating both cost-saving and time-efficient filing for ISO 15189 accreditation and compliance with the new CE-IVD Directive."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.